Glucose metabolism in the pathogenic free-living amoebae : Tempting targets for treatment development
© 2023 The Authors. Chemical Biology & Drug Design published by John Wiley & Sons Ltd..
Pathogenic free-living amoebae (pFLA) are single-celled eukaryotes responsible for causing intractable infections with high morbidity and mortality in humans and animals. Current therapeutic approaches include cocktails of antibiotic, antifungal, and antimicrobial compounds. Unfortunately, the efficacy of these can be limited, driving the need for the discovery of new treatments. Pan anti-amebic agents would be ideal; however, identifying these agents has been a challenge, likely due to the limited evolutionary relatedness of the different pFLA. Here, we discuss the potential of targeting amoebae glucose metabolic pathways as the differences between pFLA and humans suggest specific inhibitors could be developed as leads for new therapeutics.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:103 |
|---|---|
| Enthalten in: |
Chemical biology & drug design - 103(2024), 1 vom: 01. Jan., Seite e14377 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Milanes, Jillian E [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antifungal Agents |
|---|
| Anmerkungen: |
Date Completed 18.01.2024 Date Revised 25.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/cbdd.14377 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM363566112 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM363566112 | ||
| 003 | DE-627 | ||
| 005 | 20240325234335.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/cbdd.14377 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1346.xml |
| 035 | |a (DE-627)NLM363566112 | ||
| 035 | |a (NLM)37864277 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Milanes, Jillian E |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Glucose metabolism in the pathogenic free-living amoebae |b Tempting targets for treatment development |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 18.01.2024 | ||
| 500 | |a Date Revised 25.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 The Authors. Chemical Biology & Drug Design published by John Wiley & Sons Ltd. | ||
| 520 | |a Pathogenic free-living amoebae (pFLA) are single-celled eukaryotes responsible for causing intractable infections with high morbidity and mortality in humans and animals. Current therapeutic approaches include cocktails of antibiotic, antifungal, and antimicrobial compounds. Unfortunately, the efficacy of these can be limited, driving the need for the discovery of new treatments. Pan anti-amebic agents would be ideal; however, identifying these agents has been a challenge, likely due to the limited evolutionary relatedness of the different pFLA. Here, we discuss the potential of targeting amoebae glucose metabolic pathways as the differences between pFLA and humans suggest specific inhibitors could be developed as leads for new therapeutics | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a drug discovery | |
| 650 | 4 | |a glucose | |
| 650 | 4 | |a metabolism | |
| 650 | 4 | |a pathogenic amoebae | |
| 650 | 4 | |a target-based drug design | |
| 650 | 7 | |a Antifungal Agents |2 NLM | |
| 700 | 1 | |a Kwain, Samuel |e verfasserin |4 aut | |
| 700 | 1 | |a Drawdy, Allyson |e verfasserin |4 aut | |
| 700 | 1 | |a Dodson, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Monaghan, Matthew T |e verfasserin |4 aut | |
| 700 | 1 | |a Rice, Christopher A |e verfasserin |4 aut | |
| 700 | 1 | |a Dominy, Brian N |e verfasserin |4 aut | |
| 700 | 1 | |a Whitehead, Daniel C |e verfasserin |4 aut | |
| 700 | 1 | |a Morris, James C |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Chemical biology & drug design |d 2006 |g 103(2024), 1 vom: 01. Jan., Seite e14377 |w (DE-627)NLM160848377 |x 1747-0285 |7 nnns |
| 773 | 1 | 8 | |g volume:103 |g year:2024 |g number:1 |g day:01 |g month:01 |g pages:e14377 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/cbdd.14377 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 103 |j 2024 |e 1 |b 01 |c 01 |h e14377 | ||